SymBio Pharmaceuticals

Basic Information

Stock Code
4582
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
March 2005
Listing Year
October 2011
Official Website
https://www.symbiopharma.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, BrightPath, Solasia Pharma, Modalis

Overview

SymBio Pharmaceuticals is a drug discovery venture founded in 2005, specializing in the development of treatments for cancer and rare diseases, leveraging its unique new drug development platform as a pharmaceutical company.

Current Situation

SymBio Pharmaceuticals recorded net sales of approximately 5.6 billion yen for the fiscal year ended December 2023, but continues to report losses on the profit front. Its core business focuses on research and development of cancer treatments and pharmaceuticals for rare diseases, with product sales conducted through distribution agents such as Eisai, as well as direct sales by the company itself. A distinctive feature is its business model that introduces promising development candidates from overseas using its proprietary drug discovery model and aims for rapid development. In 2023, it established proof-of-concept (PoC) in clinical trials for a new antiviral drug and is focusing on clinical development. It has also entered into a collaborative research agreement with the U.S. NIH, building a global research framework. Its financial base is solid, with paid-in capital of approximately 18 billion yen and net assets of approximately 7.2 billion yen. Looking ahead, it aims to expand R&D targeting the growing rare disease market and business growth through global expansion, promoting mid- to long-term strategies for sustainable growth.

Trivia

Interesting Facts

  • Representative Japanese company as a drug discovery venture specialized in rare diseases.
  • One of the few domestic companies with direct contracts with the U.S. NIH's National Institute of Allergy and Infectious Diseases.
  • Realizes rapid clinical PoC acquisition through its proprietary new drug development platform.
  • Main product Treakisym has been used in the market for over 10 years.
  • Antiviral drug Brincidofovir attracts high attention domestically and internationally.
  • Began direct sales in the late 2010s to improve profit structure.
  • IPO in 2011, currently listed on the Tokyo Stock Exchange Growth Market.
  • Paid-in capital of approximately 18 billion yen provides stable financial base for a drug discovery venture.
  • Approximately 100 employees in a compact organizational structure.
  • Office in Toranomon, Minato-ku, Tokyo, serves as a hub for urban medical-related business.
  • Numerous collaborations with prominent domestic and international research institutions.
  • Development model offers significant benefits from utilizing prior PoC data.
  • Aims for growth through frequent technology alliances and licensing agreements with other companies.
  • Actively engages in communication with investors even after listing.
  • Maintains transparency by publicly disclosing detailed pipeline information on its website.

Hidden Connections

  • Entered into joint research agreement with U.S. National Institute of Neurological Disorders and Stroke (NINDS) to absorb cutting-edge technology.
  • Secures stable distribution through sales agency contracts with major Japanese pharmaceutical companies.
  • Collaborates with domestic biotech ventures in complementary relationships in refractory disease treatment fields.
  • Contributes to infectious disease countermeasures through antiviral drug development.
  • Future expansion of sales network in Asian markets including Japan is anticipated.
  • In-house R&D department features many physicians and pharmacists strong in clinical development.
  • Capital structure supported by domestic and international institutional investors.
  • Contributes to regional healthcare by focusing on high-public-interest rare disease treatments.

Future Outlook

Growth Drivers

  • Growth in pharmaceutical market targeting rare diseases
  • Increasing demand for antiviral drugs
  • Strengthening of global clinical development framework
  • Expanded utilization of proprietary drug discovery platform
  • Revenue base reinforcement through direct sales expansion
  • Improved drug discovery efficiency using AI and other advanced technologies
  • Product rollout expansion in Asia and North America
  • Promotion of collaboration in precision medicine field
  • Strengthening of government support measures for rare diseases
  • Increasing needs for infectious disease countermeasures
  • Avoiding market impact from biosimilars and generics
  • Sophistication of clinical trial platform

Strategic Goals

  • Establish world market share in new drugs for rare diseases
  • Expansion of global joint research and creation of results
  • Expansion of product portfolio in antiviral field
  • Increase direct sales ratio to over 50%
  • Promotion of diversification into new business areas
  • Continuous acquisition of technology patents and strengthening of intellectual property
  • Thorough implementation of sustainability and social responsibility
  • Expansion and dissemination of patient support services
  • Innovation in drug discovery and clinical development through AI utilization
  • Achieve operating profit black ink by 2030

Business Segments

Pharmaceutical Development Partnerships

Overview
Collaborates with other companies and research institutions to efficiently advance new drug development.
Competitiveness
Rapid clinical PoC acquisition and global collaboration
Customers
  • Pharmaceutical companies
  • Biotech ventures
  • Universities and research institutions
  • Medical institutions
Products
  • Anticancer agent development support
  • Antiviral drug joint research
  • Clinical trial contracting
  • Product licensing

Product Sales Agency Services

Overview
Promotes market penetration through sales of key pharmaceuticals.
Competitiveness
Close relationships maintained with sales agents
Customers
  • Medical institutions
  • Wholesalers
  • Pharmacies
  • Hospitals
Products
  • Anticancer agent sales
  • Antiviral drug sales

Global Market Development

Overview
Advances development and sales targeting overseas markets.
Competitiveness
Joint development with North American and European research institutions
Customers
  • Overseas pharmaceutical companies
  • International research institutions
  • Multinational sales partners
Products
  • New drug licensing for overseas markets
  • International clinical trial collaboration

Competitive Advantage

Strengths

  • Proprietary new drug development platform
  • Product lineup specialized for rare diseases
  • Global research partnerships
  • Rapid clinical PoC acquisition capability
  • Financial stability from ample capital
  • Strong expertise in clinical development
  • Collaborative research framework with U.S. NIH
  • Diverse product pipeline
  • Established sales channels in Japan
  • Deployment of both direct and agent sales
  • Technological superiority in focus areas
  • Capability to respond to rare disease market growth
  • High R&D capabilities
  • Securing of highly specialized talent
  • Market trust as a listed company

Competitive Advantages

  • Strength in niche market centered on rare diseases
  • Leveraging global joint research network
  • Focused investment in promising new drug candidates with PoC
  • Commercialization of multiple anticancer and antiviral drugs
  • Potential for improved profitability through direct sales
  • Sustained R&D through strong capital base
  • International credibility from contract with U.S. National Institutes of Health
  • Early market entry advantage in rare disease areas
  • Risk mitigation through diversified product portfolio
  • Revenue diversification via domestic and international sales networks
  • Building competitive barriers through functional patents
  • Accelerated technological innovation via joint research with experts
  • Product rollout addressing unmet market needs
  • Shortened commercialization timeline through rapid clinical development
  • Differentiated drug discovery business model

Threats

  • Competition in new drug development from major pharmaceutical rivals
  • Risk of clinical trial failures
  • Increased development costs due to stricter regulations
  • Limited demand in rare disease market
  • Funding difficulties from prolonged financial losses
  • Uncertainty in global markets
  • Growing pressure to lower drug prices
  • Risk of technology leakage and IP disputes
  • Intensified competition from diversified treatments
  • Impact of economic fluctuations on R&D investment
  • High dependence on outcomes from U.S. joint research
  • Development schedule delays due to pandemics, etc.

Innovations

2024: Brincidofovir Use Patent Obtained

Overview
Obtained a new use patent for Brincidofovir injection in Japan.
Impact
Expected to secure market exclusivity for rare disease treatment drug.

2023: Phase II Clinical Trial Success for Adenovirus Infection

Overview
Established clinical PoC for injection against adenovirus infection post-hematopoietic stem cell transplantation.
Impact
Contributes to enhanced reliability of treatment drug development.

2023: Joint Research Agreement with U.S. NIH

Overview
Entered into multiple collaborative research agreements (CRADA) with the U.S. National Institutes of Health.
Impact
Strengthens technological capabilities through international joint development.

2022: Enhancement of Anticancer Agent Development Platform

Overview
Advanced introduction of new anticancer agent candidate compounds and sophistication of drug discovery infrastructure.
Impact
Achieves improved development success rate and efficiency.

2021: Expansion of Direct Sales Infrastructure

Overview
Diversified revenue base by launching direct sales of anticancer agent Treakisym.
Impact
Profit improvement effect from increased direct sales.

Sustainability

  • Patient support through contributions to rare disease treatments
  • Thorough management of pharmaceutical safety information
  • Ensuring transparency in R&D activities
  • Ethical clinical trials compliant with international standards
  • Support for medical service provision through strengthened cooperation with local medical institutions